Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, announced it has entered into a definitive agreement to be acquired by AstraZeneca. The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and…
AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the Company’s climate action, restore nature, promote biodiversity and build…
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. The boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion…
Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. According to AstraZeneca, this collaboration agreement is also expected to accelerate Korean bio-health innovation. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutics, which…
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the purchase of a state-of-the-art commercial manufacturing facility in Boulder, Colorado USA. The facility, formerly owned by AstraZeneca, will provide AGC Biologics with additional capacity and significantly larger production scale. The facility is expected to begin full-scale operations and manufacturing by April 2021.…
AstraZeneca has come out with its list of strategic priorities while the company plans a return to growth and achieve scientific leadership. The actionables being announced during the investors day briefing , introduces a series of measures that would lead to efforts and resources getting rightfully directed towards the businesses priority growth platforms…
AstraZeneca has appointed Marc Dunoyer in the newly created role of Executive Vice President, Global Portfolio & Product Strategy. Marc will be responsible for driving business strategy, including business development, mergers and acquisitions, portfolio and product strategies. His most critical priorities will be to bolster the core growth platforms and therapy areas through well…
AstraZeneca has been facing a slump in sales following the loss of patent cover on antipsychotic Seroquel last month. Some of its best selling drugs – Nexium and Crestor would be loosing their patent protection in 2014 and 2016 respectively. While the company’s profits have fallen by 19 % in the first quarter the company…